The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27692854 |
100 |
N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity. |
Boehringer Ingelheim Pharmaceuticals |
| 26509831 |
29 |
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. |
Shandong University |
| 26191361 |
6 |
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. |
Emory University |
| 26096680 |
17 |
Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents. |
Virginia Commonwealth University |
| 25893046 |
77 |
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5. |
Bristol-Myers Squibb |
| 25638498 |
23 |
Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists. |
Zhejiang University |
| 24731275 |
21 |
Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents. |
Virginia Commonwealth University |
| 24563723 |
10 |
Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc. |
The Scripps Research Institute |
| 24316669 |
21 |
Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. |
Zhejiang University |
| 24095757 |
24 |
Design, syntheses, and characterization of pharmacophore based chemokine receptor CCR5 antagonists as anti prostate cancer agents. |
Virginia Commonwealth University |
| 24090135 |
201 |
Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication. |
Sanofi |
| 24900677 |
8 |
Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders. |
Therachem Research Medilab (India) |
| 21539377 |
62 |
Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. |
Glaxosmithkline |
| 20627722 |
89 |
Identification of a sulfonamide series of CCR2 antagonists. |
Glaxosmithkline |
| 18811134 |
41 |
Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. |
Glaxosmithkline |
| 22957890 |
174 |
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors. |
University of Copenhagen |
| 16629828 |
11 |
The discovery of tropane-derived CCR5 receptor antagonists. |
TBA |
| 23075267 |
85 |
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis. |
Bristol-Myers Squibb |
| 22931505 |
69 |
Chemokine receptor antagonists. |
National Heart and Lung Institute |
| 24900457 |
30 |
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication. |
TBA |
| 22901310 |
18 |
Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents. |
Virginia Commonwealth University |
| 22770928 |
15 |
The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents. |
Virginia Commonwealth University |
| 22608963 |
109 |
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity. |
Astrazeneca |
| 21765967 |
10 |
Screening for GPCR Ligands Using Surface Plasmon Resonance. |
TBA |
| 21128663 |
26 |
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). |
Pfizer |
| 20542438 |
41 |
Discovery of orally available spirodiketopiperazine-based CCR5 antagonists. |
Minase Research Institute |
| 20561788 |
33 |
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 1: Tuning the N-substituents. |
Chinese Academy of Sciences |
| 20417098 |
30 |
Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. |
Roche Palo Alto |
| 20137937 |
13 |
Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc. |
Roche Palo Alto |
| 19185490 |
27 |
1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2. |
Pfizer |
| 19171484 |
42 |
1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1. |
Pfizer |
| 18194864 |
20 |
Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. |
K£Mia |
| 18267361 |
56 |
Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. |
Novartis Institutes For Biomedical Research |
| 17118654 |
21 |
Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite. |
Ono Pharmaceutical |
| 16821774 |
86 |
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists. |
Ono Pharmaceutical |
| 14521412 |
103 |
Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. |
Lindsley F. Kimball Research Institute |
| 11931608 |
17 |
Inhibition of protein-protein association by small molecules: approaches and progress. |
Pfizer |
| 12639564 |
23 |
Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides. |
Schering-Plough Research Institute |
| 11378372 |
10 |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. |
Merck Research Laboratories |
| 22266038 |
55 |
Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. |
Astrazeneca |
| 22225639 |
29 |
Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2). |
Bristol-Myers Squibb |
| 22033460 |
38 |
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
Genzyme |
| 21940167 |
12 |
Design and synthesis of a library of chemokine antagonists. |
Novartis Institutes of Biomedical Research |
| 21820898 |
12 |
The natural product CCR5 antagonist anibamine and its analogs as anti-prostate cancer agents. |
Virginia Commonwealth University |
| 21658961 |
72 |
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist. |
Ono Pharmaceutical |
| 21398122 |
38 |
Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. |
Genzyme |
| 21341682 |
37 |
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. |
Telik |
| 24900235 |
25 |
Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity. |
TBA |
| 21295478 |
81 |
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist. |
Incyte |
| 21256008 |
44 |
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate. |
Ono Pharmaceutical |
| 21035337 |
38 |
Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion. |
Glaxosmithkline |
| 20855212 |
56 |
Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series. |
Roche Palo Alto |
| 20674358 |
14 |
Studies on the structure-activity relationship of 1,3,3,4-tetra-substituted pyrrolidine embodied CCR5 receptor antagonists. Part 2: Discovery of highly potent anti-HIV agents. |
Chinese Academy of Sciences |
| 20347189 |
7 |
Efficient synthesis and identification of novel propane-1,3-diamino bridged CCR5 antagonists with variation on the basic center carrier. |
Institute of Materia Medica |
| 20457517 |
21 |
Synthesis, SAR and evaluation of [1,4']-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists. |
Roche Palo Alto |
| 20297846 |
33 |
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. |
Genzyme |
| 20207141 |
2 |
Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach. |
Institute of Materia Medica |
| 20176481 |
15 |
Evaluation of a 4-aminopiperidine replacement in several series of CCR5 antagonists. |
Roche Palo Alto |
| 19674898 |
31 |
Spiropiperidine CCR5 antagonists. |
Roche Palo Alto |
| 20005712 |
14 |
Spirodiketopiperazine-based CCR5 antagonists: Improvement of their pharmacokinetic profiles. |
Minase Research Institute |
| 20004099 |
52 |
Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles. |
Roche Palo Alto |
| 19237282 |
47 |
Design, synthesis, and structure-activity relationship of novel CCR2 antagonists. |
Merck Research Laboratories |
| 19233649 |
30 |
[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring. |
Glaxosmithkline |
| 19167884 |
16 |
The design and discovery of novel amide CCR5 antagonists. |
Pfizer |
| 19014885 |
32 |
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist. |
Roche Palo Alto |
| 18538451 |
109 |
Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors. |
Beijing University of Technology |
| 16872138 |
2 |
Chemokine receptor CCR-5 inhibitors produced by Chaetomium globosum. |
Schering-Plough Research Institute |
| 15497939 |
2 |
Inhibition of the human chemokine receptor CCR5 by variecolin and variecolol and isolation of four new variecolin analogues, emericolins A-D, from Emericella aurantiobrunnea. |
Merlion Pharmaceuticals |
| 15217290 |
4 |
Isolation and structure of antagonists of chemokine receptor (CCR5). |
Merck Research Laboratories |
| 12932138 |
3 |
10-Methoxydihydrofuscin, fuscinarin, and fuscin, novel antagonists of the human CCR5 receptor from Oidiodendron griseum. |
Merlion Pharmaceuticals |
| 17587570 |
34 |
Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma. |
Johnson & Johnson Pharmaceutical Research and Development |
| 17461566 |
11 |
Discovery of 3-piperidinyl-1-cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists. |
Merck Research Laboratories |
| 17314043 |
38 |
CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. |
Berlex Biosciences |
| 17311371 |
13 |
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. |
Cnrs Umr 7175-Lc1 |
| 17088058 |
40 |
Diaryl substituted pyrazoles as potent CCR2 receptor antagonists. |
Merck Research Laboratories |
| 17081751 |
47 |
CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives. |
Berlex Biosciences |
| 16884289 |
26 |
Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists. |
Merck Research Laboratories |
| 16782336 |
9 |
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. |
Pfizer |
| 16698264 |
37 |
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists. |
Merck Research Laboratories |
| 16640339 |
41 |
Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity. |
Takeda Pharmaceutical |
| 16631366 |
26 |
Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides. |
Astrazeneca |
| 16539392 |
29 |
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. |
Takeda Pharmaceutical |
| 16154744 |
32 |
Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides. |
Astrazeneca |
| 15808483 |
30 |
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. |
Merck Research Laboratories |
| 15771462 |
125 |
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. |
Pharmaceutical Research Institute |
| 15686896 |
19 |
Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane. |
Merck Research Laboratories |
| 15582404 |
68 |
Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas. |
Astrazeneca |
| 15454223 |
9 |
Three new compounds from the plant Lippia alva as inhibitors of chemokine receptor 5 (CCR5). |
Schering-Plough Research Institute |
| 15177481 |
16 |
Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists. |
Merck Research Laboratories |
| 15177445 |
25 |
Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor. |
Merck Research Laboratories |
| 15115380 |
24 |
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagoni |
Schering-Plough Research Institute |
| 15055994 |
99 |
Orally bioavailable competitive CCR5 antagonists. |
Novartis Institutes For Biomedical Research |
| 15012999 |
166 |
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment. |
Merck Research Laboratories |
| 15012998 |
15 |
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds. |
Merck Research Laboratories |
| 15012997 |
43 |
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. |
Merck Research Laboratories |
| 12639563 |
4 |
Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist. |
Schering-Plough Research Institute |
| 12565973 |
33 |
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. |
Schering-Plough Research Institute |
| 12565944 |
47 |
1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains. |
Merck Research Laboratories |
| 12467630 |
25 |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains. |
Merck Research Laboratories |
| 12372534 |
2 |
Two selective novel triterpene glycosides from sea cucumber, Telenata Ananas: inhibitors of chemokine receptor-5. |
Schering-Plough Research Institute |
| 12270193 |
23 |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. |
Merck Research Laboratories |
| 12270192 |
15 |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity. |
Merck Research Laboratories |
| 11844699 |
16 |
CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. |
Merck Research Laboratories |
| 11720860 |
12 |
Combinatorial synthesis of CCR5 antagonists. |
Merck Research Laboratories |
| 11720852 |
51 |
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. |
Merck Research Laboratories |
| 11720851 |
52 |
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. |
Merck Research Laboratories |
| 11591514 |
61 |
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. |
Merck Research Laboratories |
| 11585438 |
21 |
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. |
Schering-Plough Research Institute |
| 11585437 |
17 |
Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. |
Schering-Plough Research Institute |
| 11549450 |
55 |
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. |
Merck Research Laboratories |
| 11549449 |
28 |
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes. |
Merck Research Laboratories |
| 11514156 |
28 |
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. |
Schering-Plough Research Institute |
| 11311066 |
76 |
Design, synthesis, and discovery of a novel CCR1 antagonist. |
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories |
| 11212110 |
1 |
Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. |
Kyoto University |
| 11206474 |
51 |
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. |
Merck Research Laboratories |
| 11206473 |
36 |
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. |
Merck Research Laboratories |
| 10969972 |
39 |
CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. |
Smithkline Beecham Pharmaceuticals |
| 10821717 |
29 |
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. |
Takeda Chemical Industries |
| 30891130 |
16 |
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. |
Bristol-Myers Squibb |
| 31742400 |
125 |
Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5. |
Leiden University |
| 23682308 |
16 |
A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities. |
Virginia Commonwealth University |
| 23409871 |
48 |
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. |
Glaxosmithkline |
| 30234300 |
70 |
Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists. |
University of Chinese Academy of Sciences |
| 29620890 |
25 |
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. |
Glaxosmithkline |
| 28082070 |
5 |
Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase. |
Peking University |
| 29425816 |
6 |
Recent updates for designing CCR5 antagonists as anti-retroviral agents. |
Nirma University |
| 29805075 |
28 |
Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrido[4,3-c]azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy. |
Shanghai Institute of Materia Medica |
| 28128944 |
96 |
Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase? (PI3K?) Inhibitors. |
University Park Nottingham |
| 29406702 |
128 |
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists. |
Gsk Pharmaceuticals R & D |
| 28463783 |
17 |
Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold. |
Universit£T M£Nster |
| 18676143 |
38 |
Potent and selective pyrazole-based inhibitors of B-Raf kinase. |
Array Biopharma |
Search and Browse
